As the latest generation of sodium-glucose cotransporter-2 inhibitors (SGLT2i), ertugliflozin (ERT) has stable molecular structure, long half-life, significant hypoglycemic effect and good tolerance. It also has the protective effect of heart independent of its hypoglycemic activity. It is recommended as a priority treatment for the patients with type 2 diabetes mellitus (T2DM) complicated with atherosclerotic cardiovascular disease (ASCVD) in China and abroad. In addition, ERT has a concrete effect on controlling the body weight of T2DM patients, thus also has the value in the treatment of T2DM patients with obesity. However, ERT is not recommended to be used in those T2DM patients with renal insufficiency due to low safety profile.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |